Jazz Pharmaceuticals plc [JAZZ] stock prices are up 2.39% to $123.60 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JAZZ shares have gain 0.37% over the last week, with a monthly amount drifted -3.24%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on December 12, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $175 from $140. Previously, Goldman started tracking the stock with Buy rating on June 05, 2024, and set its price target to $169. On January 03, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $160 on the stock. UBS downgraded its rating to a Neutral and decreased its price target to $135 on November 27, 2023. Raymond James initiated its recommendation with a Mkt Perform. In a note dated December 09, 2022, Goldman upgraded an Buy rating on this stock and revised its target price from $192 to $190.
The stock price of Jazz Pharmaceuticals plc [JAZZ] has been fluctuating between $99.06 and $134.17 over the past year. Currently, Wall Street analysts expect the stock to reach $182.75 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $123.60 at the most recent close of the market. An investor can expect a potential return of 47.86% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
The Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 3.99B for trailing twelve months, representing a surge of 8.52%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 122.03 points at the first support level, and at 120.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 126.13, and for the 2nd resistance point, it is at 128.66.
Ratios To Look Out For
It’s worth pointing out that Jazz Pharmaceuticals plc [NASDAQ:JAZZ]’s Current Ratio is 4.26. Also, the Quick Ratio is 3.74, while the Cash Ratio stands at 2.15. Considering the valuation of this stock, the price to sales ratio is 1.87, the price to book ratio is 1.79 and price to earnings (TTM) ratio is 17.80.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Dec 02 ’24 when 2000.0 shares were sold. SVP, Chief Accounting Officer, Carr Patricia completed a deal on Dec 02 ’24 to sell 53.0 shares. Meanwhile, Officer COZADD BRUCE C bought 2000.0 shares on Dec 02 ’24.
